Evidence map›Paper›PMID 36633503›Full record

ArticleJournal of peptide science : an official publication of the European Peptide Society2023

Modulation of the antagonistic properties of an insulin mimetic peptide by disulfide bridge modifications.

Marta Lubos, Jan Pícha, Irena Selicharová, Jíří Žák, Miloš Buděšínský, Katarína Mitrová, Lenka Žáková, Jiří Jiráček

Open access · hybridAbstract read
In one paragraph

Article in Journal of peptide science : an official publication of the European Peptide Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Modulation of the antagonistic properties of an insulin mimetic peptide by disulfide bridge modifications.Journal of peptide science : an official publication of the European Peptide Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Marta LubosInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic.
Jan PíchaInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic.
Irena SelicharováInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic.
Jíří ŽákInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic.
Miloš BuděšínskýInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic.
Katarína MitrováInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic.
Lenka ŽákováInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic.
Jiří JiráčekInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic.
Institute of Organic Chemistry · PLCzech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZ

Funding

Medical Research Council MR/R009066/1
6 · The paper itself

Abstract

Insulin is a peptide responsible for regulating the metabolic homeostasis of the organism; it elicits its effects through binding to the transmembrane insulin receptor (IR). Insulin mimetics with agonistic or antagonistic effects toward the receptor are an exciting field of research and could find applications in treating diabetes or malignant diseases. We prepared five variants of a previously reported 20-amino acid insulin-mimicking peptide. These peptides differ from each other by the structure of the covalent bridge connecting positions 11 and 18. In addition to the peptide with a disulfide bridge, a derivative with a dicarba bridge and three derivatives with a 1,2,3-triazole differing from each other by the presence of sulfur or oxygen in their staples were prepared. The strongest binding to IR was exhibited by the peptide with a disulfide bridge. All other derivatives only weakly bound to IR, and a relationship between increasing bridge length and lower binding affinity can be inferred. Despite their nanomolar affinities, none of the prepared peptide mimetics was able to activate the insulin receptor even at high concentrations, but all mimetics were able to inhibit insulin-induced receptor activation. However, the receptor remained approximately 30% active even at the highest concentration of the agents; thus, the agents behave as partial antagonists. An interesting observation is that these mimetic peptides do not antagonize insulin action in proportion to their binding affinities. The compounds characterized in this study show that it is possible to modulate the functional properties of insulin receptor peptide ligands using disulfide mimetics.

Indexed as

InsulinReceptor, InsulinDisulfidesPeptidesDisulfidesInsulinPeptidesReceptor, Insulinantagonismdicarbadisulfide mimeticsinsulin mimetic peptideinsulin receptorstapletriazole

Identifiers

PMID36633503
PMCPMC10909431
OpenAlexW4315754321

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.